Exposing the Hidden Costs: Hospitals Charging 500% More for Medicines

By Staff Writer

August 8, 2023

A recent analysis by The Moran Company has shed light on an alarming trend in the healthcare industry. On average, hospitals are charging a staggering 500% of what they paid for medicines. This practice is not only driving up costs for patients, but it’s also padding the profits of hospitals, insurers, and PBMs at the patient’s expense.

The study analysed 20 medicines and found that hospitals charged between two to seven times more than what they paid for them. This trend was initially identified in 2018 and has continued ever since. Even after negotiations with commercial payers, hospitals are still reimbursed almost 200% of what they paid to acquire the medicine.

Stephen J. Ubl, president and CEO of PhRMA, stated, “Hospital markups are driving up patients’ out-of-pocket costs, which particularly hurts patients living paycheck-to-paycheck and those in need of extensive medical care.”

Interestingly, despite a strong focus on drug spending, nearly 30% of every healthcare dollar in the United States is attributed to hospitals. Almost four times more is spent on hospitals than on retail prescription medicines annually, a trend predicted to continue indefinitely.

The study also pointed out that nearly 60% of all U.S. hospitals participate in the 340B drug pricing program, where medicines are purchased at substantial discounts. However, it’s estimated that these hospitals are reimbursed almost three times the discounted 340B price of a medicine.

As discussions continue on healthcare costs and affordability, policymakers must consider the increasing role hospitals play in driving costs for patients and the broader healthcare system.

Reference url

Recent Posts

FDA warning Aspen Pharmacare
   

FDA Warning Aspen Pharmacare: Evaluating Compliance Violations and Their Impact

🚨 Is your pharmaceutical brand prepared for FDA scrutiny?

Aspen Pharmacare Holdings recently faced a serious FDA warning highlighting significant violations in its manufacturing practices. These issues not only jeopardize product quality but also threaten access to vital medicines for patients.

Explore the implications of regulatory compliance on brand reputation and global supply in the full article!

#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess

pharmaceutical innovation 2025
      

Pharmaceutical Innovation and Market Access: Insights from Fast Company’s 2025 Top List

💊 Explore how top pharma companies are driving change in 2025! This article breaks down key innovations and smart access strategies from Fast Company’s most impactful list—giving you actionable insights into pharma innovation and market access 2025. 🚀

#SyenzaNews #pharmaceuticals #AIinHealthcare #innovation

global partnerships SCD
    

Global Partnerships SCD in Africa

🌍 How can global partnerships transform care for sickle cell disease in Africa?

In the latest article, we explore the significant strides made by the SickleInAfrica consortium, which highlights the power of collaboration in enhancing SCD management through comprehensive patient registries, clinical guidelines, and innovative research. These efforts not only improve health outcomes but also pave the way for sustainable solutions across the continent.

Dive deeper into this crucial conversation and discover how international forums are shaping the future of SCD care!

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.